课题基金 / 基金详情

LONG-TERM METABOLIC ASSESSMENTS IN SUBJECTS TREATED WITH EMTRICITABINE/TENOFO

LONG-TERM METABOLIC ASSESSMENTS IN SUBJECTS TREATED WITH EMTRICITABINE/TENOFO
恩曲他滨/替诺福治疗受试者的长期代谢评估
批准号:
7952244
负责人:
ERIC S DAAR
金额:
$6.36万
依托单位国家:
美国
项目类别:
财政年份:
2008
资助国家:
美国
项目状态:
已结题
起止时间:
2008-12-01 至 2009-11-30

项目摘要

项目成果

ERIC S DAAR的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to see if taking a uridine supplement (NucleomaxX¿) is safe in HIV-infected persons and if it will reverse loss of fat in the face, arms, legs, or buttocks. The study will also try to see how well NucleomaxX is tolerated. NucleomaxX is a powdered nutritional food supplement that contains a substance called uridine. It comes in a sachet (packet) and needs to be mixed in with juice, milk, or water. NucleomaxX is used in Europe as a food supplement but is not approved by the U.S. Food and Drug Administration (FDA) and is considered an experimental drug in the U.S About 164 people will take part in this study across the country. About 20 will take part in it at this site.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
An integrated intervention using a pill ingestible sensor system to trigger actions on multifaceted social and behavioral determinants of health among PLWH
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System
Measuring and Monitoring Adherence to ART with Pill Ingestion Sensor System
CLINICAL TRIAL: A PHASE III COMPARATIVE STUDY OF THREE NON-NUCLEOSIDE REVERSE TR
海外基金